Akari Therapeutics, Plc Shareholders' Equity
Akari Therapeutics, Plc (AKTX) had Shareholders' Equity of $18.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $18.59M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $14.38M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $28.33M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $22.69M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $18.59M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $14.38M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $28.33M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $22.69M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $25.61M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $21.75M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $22.23M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | -$6.69M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$3.70M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | -$3.55M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | -$229.00K 10-K · filed 2026-03-30 | |
| 2023-09-30 | $213.00K 10-Q · filed 2024-11-19 | |
| 2023-06-30 | $2.78M 10-Q · filed 2024-11-19 | $2.78M 6-K · filed 2023-09-29 |
| 2023-03-31 | $6.56M 10-Q · filed 2024-11-19 | |
| 2022-12-31 | $1.79M 10-K · filed 2025-04-15 | $1.79M 20-F · filed 2023-05-01 |
| 2022-06-30 | $8.33M 6-K · filed 2023-09-29 | |
| 2022-03-31 | $13.93M 6-K · filed 2022-09-27 | |
| 2021-12-31 | -$1.94M 8-K · filed 2024-09-06 | $5.55M 20-F · filed 2022-05-16 |
| 2021-06-30 | $1.59M 6-K · filed 2022-09-27 | |
| 2021-03-31 | $3.94M 6-K · filed 2022-09-27 | |
| 2020-12-31 | $9.38M 20-F · filed 2023-05-01 | |
| 2020-09-30 | $6.95M 20-F · filed 2021-04-21 | |
| 2020-06-30 | $5.96M 6-K · filed 2021-09-22 | $3.34M 6-K · filed 2020-09-01 |
| 2020-03-31 | $3.27M 6-K · filed 2021-09-22 | $1.82M 6-K · filed 2020-09-01 |
| 2019-12-31 | $7.60K 20-F · filed 2023-05-01 | -$1.77M 20-F · filed 2020-03-31 |
| 2019-09-30 | $4.90M 20-F · filed 2021-04-21 | |
| 2019-06-30 | $459.37K 20-F · filed 2021-04-21 | -$1.37M 6-K · filed 2019-08-29 |
| 2019-03-31 | $4.84M 20-F · filed 2021-04-21 | $1.22M 6-K · filed 2019-08-29 |
| 2018-12-31 | $4.37M 20-F · filed 2022-05-16 | $3.11M 20-F · filed 2019-04-23 |
| 2018-06-30 | $8.63M 6-K · filed 2019-08-29 | |
| 2018-03-31 | $16.32M 6-K · filed 2019-08-29 | |
| 2017-12-31 | $22.24M 20-F · filed 2021-04-21 | $17.15M 20-F · filed 2018-07-18 |
| 2017-06-30 | $22.85M 6-K · filed 2017-08-10 | |
| 2016-12-31 | $34.10M 20-F · filed 2019-04-23 | |
| 2016-06-30 | $40.58M 6-K · filed 2017-04-14 | |
| 2016-03-31 | $46.36M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $48.72M 20-F · filed 2019-04-23 | |
| 2015-09-30 | $41.33M 10-Q · filed 2015-11-23 | |
| 2015-06-30 | $973.00K 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $2.60M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $2.22M 20-F · filed 2018-07-18 | $4.85M 10-K · filed 2015-02-11 |
| 2014-06-30 | $10.41M 10-Q · filed 2015-08-12 | |
| 2013-12-31 | $400.69K 20-F · filed 2017-03-31 | $5.81M 20-F · filed 2014-03-24 |
| 2012-12-31 | -$3.36M 10-K · filed 2015-02-11 | |
| 2011-12-31 | -$2.48M 10-K · filed 2015-02-11 | |
| 2010-12-31 | -$2.00M 20-F · filed 2014-03-24 | |
| 2009-12-31 | -$1.70M 20-F · filed 2014-03-24 | |
| 2008-12-31 | -$1.26M 20-F · filed 2014-03-24 | |
| 2007-12-31 | -$60.00K 20-F · filed 2014-03-24 | |
| 2006-12-31 | -$467.00K 20-F · filed 2014-03-24 | |
| 2005-12-31 | $1.23M 20-F · filed 2014-03-24 | |
| 2004-10-06 | $0.00 20-F · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |